Hospital Groups to CMS: Don’t Rob Some Hospitals to Repay 340B Hospitals for Your Illegal Drug Payment Cuts

AHA and NRHA
AHA and NRHA both urged the Biden administration not to claw back Medicare payments from some hospitals to pay for the remedy for illegal drug payment cuts for 340B hospitals.

Two hospital groups separately urged Biden administration officials this month to not divert funding from non-340B hospitals and some 340B hospitals in order to repay other 340B hospitals for almost five years’ worth of illegal Medicare Part B drug payment

Read More »

State Roundup: Lots of 340B Action as Many Legislatures Conclude Sessions

John Bel Edwards
Louisiana Gov. John Bel Edwards (D) signed a bill making his state the second to stop drug manufacturer interference with 340B contract pharmacy arrangements.

Louisiana Gov. John Bel Edwards (D) has signed legislation making his state just the second with a law addressing manufacturer conditions on deliveries of 340B-acquired drugs to contract pharmacies.

Arkansas’s Act 1103, passed in August 2021, was the first. A

Read More »

AHA Urges HRSA to Restore Policy Allowing Earlier Use of 340B Drugs in Hospital Outpatient Clinics

AHA
The American Hospital Association published a study that found 340B hospitals' community benefit increased significantly in 2020.

The American Hospital Association has asked the U.S. Health Resources and Services Administration to resume letting hospitals dispense 340B drugs at offsite clinics that have not yet appeared on the hospital’s most recently filed Medicare cost report.

AHA asked HRSA

Read More »

340B Registration for Third Quarter of 2023 Will Run from July 1 to July 17

Registration green
Q3 2023 covered entity registration for the 340B program runs from July 1 to July 17, HRSA says.

The U.S. Health Resources and Services Administration has added two days to the next quarterly 340B registration period.

A HRSA spokesperson said Friday that Q3 registration for 340B covered entities, their child sites, and their contract pharmacies will begin July

Read More »

CMS Creates New Group to Lead Medicaid Managed Care Policy

CMS
CMS has created a new group within the CMS Center for Medicaid and CHIP Services to develop and manage federal Medicaid managed care policy.

The U.S. Centers for Medicare & Medicaid Services (CMS) said this week it has created a new unit within the CMS Center for Medicaid and CHIP Services (CMCS) to develop and manage federal Medicaid managed care policy.

CMS announced the

Read More »

HHS, HRSA Tell Judge They Don’t Know When They’ll Replace 340B Dispute Resolution Process

340B administrative dispute resolution
HHS and HRSA recently told a federal district court they “are unable to predict” when they will finally replace HRSA’s 340B administrative dispute resolution proces.

The U.S. Department of Health and Human Services and the Health Resources and Services Administration “are unable to predict” when they will finally replace HRSA’s 340B administrative dispute resolution process, the government said in a recent legal filing.

The government

Read More »

HRSA Posts Four Manufacturer Notices to 340B Entities

Humalog
Lilly is providing refunds for 340B overcharges during Q1 2020 on Humalog and Trulicity.

The U.S. Health Resources and Services Administration yesterday posted notices of refunds for 340B overcharges from drug manufacturers Lilly, Novo Nordisk, and Neurocrine and a notice from Amneal about product NDC changes.

Lilly

Lilly’s May 30 notice covers purchases

Read More »

HRSA Allows Immediate 340B Enrollment in Guam Due to Typhoon

Guam typhoon Mawar
Destruction in Tamuning, Guam, caused by super typhoon Mawar, which made landfall on May 24 as a Category 4-equivalent storm.

Health care providers in Guam eligible to participate in the 340B program may do so immediately, rather than having to wait for the next normal quarterly registration period July 1-15, the U.S. Health Resources and Services Administration said yesterday.

Secretary

Read More »

Merck to Pay Refunds for 340B Overcharges in Q1 and Q2 2020

Cubicin
Merck is providing refunds for 340B overcharges on NDCs of its antibiotic Cubicin and other drugs during the first two quarters of 2020.

Drug manufacturer Merck is paying refunds for overcharges on 340B drugs purchased during the first two quarters of 2020.

Merck recently asked the U.S. Health Resources and Services Administration to post notices about its 340B ceiling price recalculations on the

Read More »

CMS Is a Step Closer to Saying How It Will Fix Medicare Drug Payment Cuts for 340B Hospitals

OMB
CMS sent its proposed remedy for illegal Medicare Part B drug payment cuts for 340B hospitals to the White House for clearance to be released.

The U.S. Centers for Medicare & Medicaid Services has sent its proposed remedy for almost five years of illegal Medicare Part B drug payments cuts for 340B hospitals to the White House for clearance to be published in the Federal

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report